Navenibart

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameNavenibart
Drug Alias NameQLS-215STAR-0215
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionPlasma kallikrein inhibitors
TargetsPlasma kallikrein
Therapy Area/IndicationsAngioedemas, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[24
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesQuellis Biosciences Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsAngioedemas, Hereditary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A